Generate Biomedicines, Inc. (GENB) shareholders
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Afeyan Noubar Joint filing with Flagship Pioneering, LLC (48.90%), Flagship VentureLabs VI Manager LLC (19.50%) and 5 more | 62,701,915 | 48.90% | 13G (passive) | Mar 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.60%) | 7,186,203 | 5.60% | 13G (passive) | Sep 30, 2026 |
| Nally Michael | 6,919,051 | 5.20% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GENB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 62,673,117 | 48.83% | $1.06B | – | 68.66% |
| FMR LLC | 5,221,599 | 4.07% | $88.09M | +1,004,075 | 0.00% |
| Capital World Investors | 4,215,632 | 3.28% | $71.12M | +211,483 | 0.01% |
| Braidwell LP | 3,283,844 | 2.56% | $55.40M | −309,155 | 2.05% |
| Price T Rowe Associates Inc /Md/ | 2,156,627 | 1.68% | $36.38M | +46,994 | 0.00% |
| Norges Bank | 2,094,616 | 1.63% | $35.34M | New | 0.00% |
| ARCH Venture Management, LLC | 1,944,426 | 1.51% | $32.80M | – | 2.98% |
| HarbourVest Partners LLC | 1,722,210 | 1.34% | $29.05M | – | 17.09% |
| BlackRock, Inc. | 1,659,966 | 1.29% | $28.00M | New | 0.00% |
| Baker Bros. Advisors LP | 1,423,602 | 1.11% | $24.02M | – | 0.12% |
| JPMorgan Chase & Co | 1,409,649 | 1.10% | $23.84M | −1,537,610 | 0.00% |
| Deep Track Capital, LP | 1,333,815 | 1.04% | $22.50M | New | 0.33% |
| ARK Investment Management LLC | 1,284,617 | 1.00% | $21.67M | +786,209 | 0.14% |
| Vanguard Capital Management LLC | 1,132,750 | 0.88% | $19.11M | +1,001,431 | 0.00% |
| Harvard Management Co Inc | 1,111,100 | 0.87% | $18.74M | – | 0.44% |
| Nvidia Corp | 833,325 | 0.65% | $14.06M | – | 0.02% |
| Davern Capital Partners, LP | 824,679 | 0.64% | $13.91M | +232,879 | 2.37% |
| Siren, L.L.C. | 736,104 | 0.57% | $12.42M | – | 0.25% |
| Geode Capital Management, LLC | 735,003 | 0.57% | $12.40M | +616,760 | 0.00% |
| State Street Corp | 526,565 | 0.41% | $8.88M | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 100M | 77.9% | 42 / 24 | 10 / 13 | 11M | 4M |
| Q1 2026 | 57 | 93M | 72.3% | 57 / 0 | 0 / 0 | 93M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GENB | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,752,630 | 2.92% | $63.31M | 0.07% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,237,891 | 0.96% | $17.33M | 1.11% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 816,876 | 0.64% | $13.78M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 634,700 | 0.49% | $8.33M | 0.01% | May 31, 2026 |
| iShares Russell 2000 ETF | 617,886 | 0.48% | $10.42M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 580,246 | 0.45% | $9.79M | 0.38% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 314,964 | 0.25% | $5.31M | 0.04% | Jun 30, 2026 |
| Eaton Vance Worldwide Health Sciences Fund | 312,500 | 0.24% | $4.10M | 0.54% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 296,479 | 0.23% | $5.00M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 267,202 | 0.21% | $3.74M | 0.01% | Jul 31, 2026 |
| JPMorgan Small Cap Blend Fund | 184,432 | 0.14% | $3.11M | 0.18% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 177,236 | 0.14% | $2.33M | 0.01% | May 31, 2026 |
| American Funds U.S. Small & Mid Cap Equity Fund | 174,326 | 0.14% | $2.29M | 0.33% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 169,300 | 0.13% | $2.22M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 157,860 | 0.12% | $2.66M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Nally | Chief Executive Officer, Director | 2,889,154 | 2.25% | Mar 6, 2026 |
| Gevorg Grigoryan | Chief Technology Officer | 659,973 | 0.51% | Mar 2, 2026 |
| Beth Grous | Chief People Officer | 300 | 0.00% | Mar 2, 2026 |
| Laurie Anne Lee | Chief Medical Officer | – | – | Mar 2, 2026 |
| Jason Silvers | President & CFO | 1,500 | 0.00% | Mar 2, 2026 |
| Sean Martin | Chief Legal Officer & GC | – | – | Mar 2, 2026 |
| Aarif Khakoo | Chief Scientific Officer | – | – | Feb 26, 2026 |
| Frances Arnold | Director | 452,535 | 0.35% | Nov 4, 2026 |
| Paul Gray Parker | Director | – | – | Mar 2, 2026 |
| Nancy A. Simonian | Director | – | – | Mar 2, 2026 |
| Jane L. Mendillo | Director | 1,500 | 0.00% | Mar 2, 2026 |
| Marsha Fanucci | Director | – | – | Mar 2, 2026 |
| Rupert Vessey | Director | – | – | Mar 2, 2026 |
| Noubar Afeyan | Director, 10% owner | – | – | Mar 2, 2026 |
| Stephane Bancel | Director | 1,184,989 | 0.92% | Mar 2, 2026 |
| Pioneering Medicines 02, LLC | 10% owner | 1,562,500 | 1.22% | Mar 12, 2026 |
| Pioneering Fund VII General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Fund VII, L.P. | 10% owner | – | – | Mar 2, 2026 |
| Pioneering Special Opportunities Fund II General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Special Opportunities Fund II, L.P. | 10% owner | – | – | Mar 2, 2026 |
| Fpn Ii, L.P. | 10% owner | – | – | Mar 2, 2026 |
| VentureLabs VI LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering Fund VI, L.P. | 10% owner | 59,548,117 | 46.39% | Mar 2, 2026 |
| Pioneering Fund VI General Partner LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| Nutritional Health LTP Fund, L.P. | 10% owner | 25,016,458 | 19.49% | Mar 2, 2026 |
| Health LTP Fund General Partner LLC Nutritional | 10% owner | 62,673,117 | 48.83% | Mar 2, 2026 |
| VentureLabs VI Manager LLC Flagship | 10% owner | – | – | Mar 2, 2026 |
| General Partner LLC FPN | 10% owner | – | – | Mar 2, 2026 |
| Flagship Pioneering, LLC | 10% owner | – | – | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Frances Arnold Director | Oct 29, 2026 | Sale(10b5-1 plan) | −11,409 | $16.19 | $184.73K | 220,063 |
| Frances Arnold Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,000 | $16.00 | $16.00K | 231,472 |
| Michael Nally Chief Executive Officer, Director | Mar 4, 2026 | Buy | +20,000 | $12.00 | $240.00K | 572,707 |
| Michael Nally Chief Executive Officer, Director | Mar 2, 2026 | Conversion | +658,327 | – | – | 1,316,654 |
| Stephane Bancel Director | Mar 2, 2026 | Conversion | +724,160 | – | – | 724,160 |
| Beth Grous Chief People Officer | Mar 2, 2026 | Buy | +300 | $16.00 | $4.80K | 300 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +13,702,224 | – | – | 13,702,224 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +987,491 | – | – | 987,491 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 15,264,724 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 4,340,252 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 1,562,500 |
| Flagship Pioneering Fund VI, L.P. 10% owner | Mar 2, 2026 | Conversion | +12,723,940 | – | – | 12,723,940 |
| Jane L. Mendillo Director | Mar 2, 2026 | Buy | +1,500 | $16.00 | $24.00K | 1,500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +500 | $16.00 | $8.00K | 500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +500 | $16.00 | $8.00K | 500 |
| Jason Silvers President & CFO | Mar 2, 2026 | Buy | +1,000 | $16.00 | $16.00K | 1,000 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 4,340,252 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 15,264,724 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +2,777,752 | – | – | 2,777,752 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Buy | +1,562,500 | $16.00 | $25.00M | 1,562,500 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +13,702,224 | – | – | 13,702,224 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +12,723,940 | – | – | 12,723,940 |
| Health LTP Fund General Partner LLC Nutritional 10% owner | Mar 2, 2026 | Conversion | +987,491 | – | – | 987,491 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 8 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Generate Biomedicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,769 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Frances Arnold Director | Oct 29, 2026 | 11,409 | $184.73K | Oct 29, 2026 | Restricted Stock Vesting |
| Frances Arnold Director | Sep 2, 2026 | 32,210 | $520.63K | Sep 2, 2026 | Restricted Stock Vesting |
| Frances Arnold Director | Sep 1, 2026 | 1,000 | $16.00K | Sep 1, 2026 | Restricted Stock Vesting |
See a number that looks wrong?